Table 2.

Univariate Survival Analysis for 1,431 high risk, non-metastatic melanoma patients.

(Key: NLR = neutrophil to lymphocyte ratio, LVI = lymphovascular invasion. nodal characteristic: Clin(−)/Path(−)/#(0) = no clinically evident lymphadenopathy, no pathologic lymph node metastases. Clin(−)/Path(+)/#(≥1) = no clinically evident lymphadenopathy, positive pathologic lymph node metastases. Clin(−)/Path(+)/#(≥1) = clinically evident lymphadenopathy, positive pathologic lymph node metastases.)

Characteristic	N (%)	Univariate	p-value
		(HR, 95% CI)
Age (years), median (IQR)	63.4 (49.9 – 73.8)	1.01 (1.00 – 1.01)	0.015
Gender
Female	550 (38.4%)	1	<0.001
Male	881 (61.6%)	1.5 (1.22 – 1.85)
White blood cell count, median (IQR)
Absolute neutrophil count	4.5 (3.6 – 5.4)	1.04 (0.97 – 1.11)	0.310
Absolute lymphocyte count	1.7 (1.3 – 2.1)	0.83 (0.69 – 0.99)	0.038
Absolute monocyte count (n=1108)	0.3 (0.3 – 0.4)	1.97 (0.91 – 4.24)	0.084
Tumor thickness, median (IQR)	2.9 (1.8 – 4.6)	1.02 (1 – 1.04)	0.013
Tumor Site
Extremity	534 (37.3%)	1	0.065
Hand/Foot	172 (12%)	1.42 (1.07 – 1.89)
Head and Neck	332 (23.2%)	0.96 (0.73 – 1.24)
Trunk	393 (27.5%)	1.14 (0.9 – 1.44)
Ulceration
Not identified/Unknown	631 (44.1%)	1	<0.001
Identified	800 (55.9%)	1.42 (1.18 – 1.72)
LVI
Not identified/Unknown	220 (15.4%)	1	<0.001
Identified	1211 (84.6%)	2.02 (1.61 – 2.54)
Nodal Characteristic
Clin(−)/Path(−)/#(0)	808 (56.5%)	1	<0.001
Clin(−)/Path(+)/#(≥1)	456 (31.9%)	1.75 (1.42 – 2.17)
Clin(+)/Path(+)/#(≥1)	167 (11.7%)	3.49 (2.67 – 4.55)
NLR
< 3	847(59.2%)	1	0.001
≥ 3	584 (40.8%)	1.39 (1.15 – 1.68)